References

The Big Asthma Lie

Asthma Causes and Treatments

Get Instant Access

1 Kerstjens HA. Stable chronic obstructive pulmonary disease. BMJ1999; 319: 495-500.

2 Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible airflow obstruction. Am Rev Respir Dis 1985; 131: 747-51.

3 Murciano D, Avclair MH, Parievte R, Aubier M. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-5.

4 Chrystyn H, Mulley BA, Peake MD. Dose-response relation to oral theophylline in severe chronic obstructive airway disease. BMJ 1988; 297: 1506-10.

5 Barnes PJ, Pauwels RA. Theophylline in asthma: time for reappraisal? Eur Respir J 1994; 7: 579-91.

6 Evans DJ, Taylor DA, Zetterstrom O et al. A comparison of low-dose inhaled budesonide plus theophylline and highdose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-18.

7 Culpitt SV, de Matos C, Russell RE et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil Chemotaxis in COPD. Am J Respir Crit Care Med 2002; 165: 1371-6.

8 Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997; 100: 1677-84.

9 Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 1996; 77: 34-8.

10 Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-8.

11 Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271-4.

12 Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-57.

13 Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22: 209-21.

14 Lundback B, Lindstrom M, Jonsson E, Anderson S, van Herwaarden C. Effect of N-acetylcysteine on the decline in lung function in patients with COPD. Eur Respir J1995; 5 (Suppl. 15): 895.

15 Fedson DS, Shapiro ED, LaForce FM etal. Pneumococcal vaccine after 15 years of use: another view. Arch Intern Med 1994; 154: 2531-5.

16 Cox NJ, Hughes JM. New options for the prevention of influenza [editorial]. N Engl J Medical 1999; 341: 1387-8.

17 Collet JP, Shapiro P, Ernst P et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997; 156: 1719-24.

18 Barnes PJ. Future advances in COPD therapy. Respiration 2001; 68: 441-8.

19 Barnes PJ. New treatments for COPD. Nature Rev Drug Disc 2002; 1: 437-45.

20 Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.

21 Barnes PJ. Tiotropium bromide. Expert Opin Invest Drugs 2001; 10: 733-40.

22 Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-4.

23 Torphy TJ. Phosphodiesterase isoenzymes. Am J Respir Crit Care Med 1998; 157: 351-70.

24 Compton CH, Gubb J, Nieman R etal. Cilomilast, a selective phosphodiesterase-

4 inhibitor for treatment of patients with chronic obstructive pulmonary disease:

a randomised, dose-ranging study. Lancet 2001; 358: 265-70.

25 Barnes PJ, Karin M. Nuclear factor-KB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.

26 Di Stefano A, Maestrelli P, Roggeri A etal. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994; 149: 803-10.

27 Underwood DC, Osborn RR, Bochnowicz

5 etal. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L895-L902.

28 Luisetti M, Sturani C, Sella D etal. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J1996; 9: 1482-6.

29 Seersholm N, Wencker M, Banik N etal. Does a1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary a1-

antitrypsin deficiency. Eur Respir J1997; 10: 2260-3.

30 Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168 (Suppl. ): 565-78.

31 Llewellyn-Jones CG, Stockley RA. Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation and extracellular proteolytic activity in vitro. Thorax 1994; 49: 207-12.

32 McElvaney NG, Doujaiji B, Moan MJ et al. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056-60.

33 Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997; 3: 675-7.

34 Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 1998; 125: 1315-24.

Was this article helpful?

0 0
Coping with Asthma

Coping with Asthma

If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.

Get My Free Ebook


Post a comment